LifeStance Health Group, Inc. (NASDAQ:LFST) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers increased its holdings in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) by 4.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 195,581 shares of the company’s stock after purchasing an additional 8,487 shares during the quarter. Rhumbline Advisers owned 0.05% of LifeStance Health Group worth $1,441,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Blue Trust Inc. increased its position in LifeStance Health Group by 124.4% during the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company’s stock worth $27,000 after purchasing an additional 2,122 shares in the last quarter. Entropy Technologies LP acquired a new stake in LifeStance Health Group during the 4th quarter worth approximately $150,000. Jennison Associates LLC increased its position in LifeStance Health Group by 278.4% during the 4th quarter. Jennison Associates LLC now owns 8,086,380 shares of the company’s stock worth $59,597,000 after purchasing an additional 5,949,438 shares in the last quarter. R Squared Ltd acquired a new stake in LifeStance Health Group during the 4th quarter worth approximately $80,000. Finally, SG Americas Securities LLC increased its position in LifeStance Health Group by 65.7% during the 4th quarter. SG Americas Securities LLC now owns 90,355 shares of the company’s stock worth $666,000 after purchasing an additional 35,823 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analyst Ratings Changes

LFST has been the subject of a number of analyst reports. The Goldman Sachs Group upgraded LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Monday, December 16th. William Blair restated an “outperform” rating on shares of LifeStance Health Group in a report on Friday, February 28th. Finally, Barclays upped their price target on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.70.

LifeStance Health Group Stock Performance

LifeStance Health Group stock opened at $8.02 on Wednesday. The stock has a market cap of $3.07 billion, a P/E ratio of -30.85 and a beta of 1.28. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $7.83 and a 200-day moving average of $7.27. LifeStance Health Group, Inc. has a 52 week low of $4.64 and a 52 week high of $8.61.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.